Exelixis: Financial Performance Improves Faster Than Market Expectations (NASDAQ:EXEL)
· seekingalpha.com
Exelixis (EXEL) looks undervalued after a 13%+ rally, backed by CABOMETYX-driven growth, rising margins, and strong FCF—see the $57 buy case now.
My investment thesis worked perfectly – the idea to buy Exelixis ( EXEL ) shares before the release of the Q1 report fully justified itself. I predicted that ...